{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:36:09Z","timestamp":1780727769191,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Doelfonds Leukemie of the Bontius Stichting"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) can boost Graft-versus-Leukaemia (GvL) reactivity but may induce Graft-versus-Host-Disease (GvHD). It is essential to understand which factors besides timing, donor type, and dose influence DLI alloreactivity. We previously identified viral infections, \u2265\u20095% patient cells in bone marrow chimerism, and lymphopenia at the time of DLI as relevant factors for GvHD after DLI following alemtuzumab-based T-cell depletion. Here, we investigated these factors and the alloreactivity after DLI following alloSCT with posttransplant cyclophosphamide in 83 patients with acute leukaemia\/myelodysplastic syndrome receiving a prophylactic or preemptive DLI. 5% had viral infections close to DLI, 6% had\u2009\u2265\u20095% mixed chimerism, and 17% had lymphopenia. 2-year cumulative incidence of GvHD requiring systemic treatment was low: 7% (95%-confidence interval 1\u201314%). 22 of the 28 patients with \u2265\u20091% mixed chimerism at the time of DLI (79%) converted to full-donor chimerism. None of these responders relapsed, indicating achievement of GvL despite the low incidence of GvHD. Our data show that DLI alloreactivity is determined by the conditions at the time of DLI which are influenced by the transplantation strategy. Adjusting the DLI dose based on these conditions may improve the balance between GvHD and GvL.<\/jats:p>","DOI":"10.1007\/s00277-025-06662-x","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:12:58Z","timestamp":1760947978000},"page":"5379-5387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8446-5133","authenticated-orcid":false,"given":"Eva A.S.","family":"Koster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-7346","authenticated-orcid":false,"given":"Peter A.","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-4249","authenticated-orcid":false,"given":"Joost G.K.","family":"van der Hem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-4664","authenticated-orcid":false,"given":"Peter","family":"van Balen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4560","authenticated-orcid":false,"given":"Erik W.A.","family":"Marijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-715X","authenticated-orcid":false,"given":"Jennifer M.L.","family":"Tjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd J.F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle","family":"van Lammeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-3125","authenticated-orcid":false,"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-4813","authenticated-orcid":false,"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9369","authenticated-orcid":false,"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-0045","authenticated-orcid":false,"given":"Constantijn J.M.","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"6662_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/978-3-031-44080-9_59","volume-title":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies","author":"JHF Falkenburg","year":"2024","unstructured":"Falkenburg JHF, Schmid C, Kolb HJ, Kuball J (2024) Delayed transfer of immune cells or the Art of donor lymphocyte infusion (DLI) 2.0. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E (eds) The EBMT handbook: hematopoietic cell transplantation and cellular therapies. Springer International Publishing, Cham, pp 531\u2013539"},{"key":"6662_CR2","doi-asserted-by":"publisher","first-page":"1335341","DOI":"10.3389\/fimmu.2024.1335341","volume":"15","author":"EAS Koster","year":"2024","unstructured":"Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF et al (2024) Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation. Front Immunol 15:1335341. https:\/\/doi.org\/10.3389\/fimmu.2024.1335341","journal-title":"Front Immunol"},{"issue":"1","key":"6662_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2006-12-022038","volume":"110","author":"R Chakraverty","year":"2007","unstructured":"Chakraverty R, Sykes M (2007) The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 110(1):9\u201317. https:\/\/doi.org\/10.1182\/blood-2006-12-022038","journal-title":"Blood"},{"key":"6662_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fimmu.2018.00331","volume":"9","author":"P van Balen","year":"2018","unstructured":"van Balen P, van der Zouwen B, Kruisselbrink AB, Eefting M, Szuhai K, Jordanova ES et al (2018) Tissue damage caused by myeloablative, but not non-myeloablative, conditioning before allogeneic stem cell transplantation results in dermal macrophage recruitment without active T-cell interaction. Front Immunol 9:331. https:\/\/doi.org\/10.3389\/fimmu.2018.00331","journal-title":"Front Immunol"},{"issue":"10","key":"6662_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/bmt.2010.300","volume":"46","author":"S Thiant","year":"2011","unstructured":"Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, Dessaint JP et al (2011) Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 46(10):1374\u20131381. https:\/\/doi.org\/10.1038\/bmt.2010.300","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"6662_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/bmt.2010.13","volume":"45","author":"S Thiant","year":"2010","unstructured":"Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al (2010) Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 45(10):1546\u20131552. https:\/\/doi.org\/10.1038\/bmt.2010.13","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"6662_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2012-12-470872","volume":"122","author":"S Stevanovic","year":"2013","unstructured":"Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB et al (2013) HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+\u2009donor lymphocyte infusion. Blood 122(11):1963\u20131973. https:\/\/doi.org\/10.1182\/blood-2012-12-470872","journal-title":"Blood"},{"key":"6662_CR8","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG (2019) Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol 10:2668. https:\/\/doi.org\/10.3389\/fimmu.2019.02668","journal-title":"Front Immunol"},{"issue":"1","key":"6662_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","volume":"15","author":"C Zhao","year":"2022","unstructured":"Zhao C, Bartock M, Jia B, Shah N, Claxton DF, Wirk B et al (2022) Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J Hematol Oncol 15(1):64. https:\/\/doi.org\/10.1186\/s13045-022-01287-3","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6662_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","volume":"18","author":"SO Ciurea","year":"2012","unstructured":"Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R et al (2012) Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1835\u20131844. https:\/\/doi.org\/10.1016\/j.bbmt.2012.07.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"6662_CR11","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","volume":"94","author":"J Tischer","year":"2015","unstructured":"Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C et al (2015) Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol 94(10):1677\u20131688. https:\/\/doi.org\/10.1007\/s00277-015-2423-y","journal-title":"Ann Hematol"},{"issue":"1","key":"6662_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ejh.13529","volume":"106","author":"J Montoro","year":"2021","unstructured":"Montoro J, Rold\u00e1n E, Pi\u00f1ana JL, Barba P, Chor\u00e3o P, Quintero A et al (2021) Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Eur J Haematol 106(1):114\u2013125. https:\/\/doi.org\/10.1111\/ejh.13529","journal-title":"Eur J Haematol"},{"issue":"11","key":"6662_CR13","doi-asserted-by":"publisher","first-page":"909.e1","DOI":"10.1016\/j.jtct.2021.08.013","volume":"27","author":"KC Rappazzo","year":"2021","unstructured":"Rappazzo KC, Zahurak M, Bettinotti M, Ali SA, Ambinder AJ, Bola\u00f1os-Meade J et al (2021) Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post- transplantation cyclophosphamide. Transpl Cell Ther 27(11):909.e1-909e6. https:\/\/doi.org\/10.1016\/j.jtct.2021.08.013","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"6662_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","volume":"105","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S et al (2020) Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica 105(1):47\u201358. https:\/\/doi.org\/10.3324\/haematol.2019.219790","journal-title":"Haematologica"},{"key":"6662_CR15","doi-asserted-by":"publisher","unstructured":"Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S et al (2021) Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination governs GVHD and immunosuppression need, reducing late toxicities in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. J Clin Med 10(6):1173. https:\/\/doi.org\/10.3390\/jcm10061173","DOI":"10.3390\/jcm10061173"},{"issue":"11","key":"6662_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41409-024-02312-4","volume":"59","author":"K Shanmugasundaram","year":"2024","unstructured":"Shanmugasundaram K, Napier S, Dimitrova D, Stokes A, Wilder J, Chai A et al (2024) Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients. Bone Marrow Transplant 59(11):1513\u20131524. https:\/\/doi.org\/10.1038\/s41409-024-02312-4","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6662_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","volume":"54","author":"L Castagna","year":"2016","unstructured":"Castagna L, Sarina B, Bramanti S, Perseghin P, Mariotti J, Morabito L (2016) Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfus Apher Sci 54(3):345\u2013355. https:\/\/doi.org\/10.1016\/j.transci.2016.05.011","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"6662_CR18","doi-asserted-by":"publisher","first-page":"183.e1","DOI":"10.1016\/j.jtct.2022.01.022","volume":"28","author":"J Ros-Soto","year":"2022","unstructured":"Ros-Soto J, Snowden JA, Szydlo R, Nicholson E, Madrigal A, Easdale S et al (2022) Outcomes after donor lymphocyte infusion in patients with hematological malignancies: donor characteristics matter. Transpl Cell Ther 28(4):183.e1-183.e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.022","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"6662_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.022","volume":"29","author":"EAS Koster","year":"2023","unstructured":"Koster EAS, von dem Borne PA, van Balen P, van Egmond EHM, Marijt EWA, Veld SAJ et al (2023) Competitive repopulation and allo-immunologic pressure determine chimerism kinetics after T cell-depleted allogeneic stem cell transplantation and donor lymphocyte infusion. Transplant Cell Ther 29(4):268.e1-268.e10. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"6662_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.bbmt.2017.02.022","volume":"23","author":"SR Solomon","year":"2017","unstructured":"Solomon SR, Sizemore C, Zhang X, Ridgeway M, Solh M, Morris LE et al (2017) Current graft-versus-host disease-free, relapse-free survival: a dynamic endpoint to better define efficacy after allogenic transplant. Biol Blood Marrow Transplant 23(7):1208\u20131214. https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.022","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"6662_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2015.136846","volume":"101","author":"M Eefting","year":"2016","unstructured":"Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW et al (2016) Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. Haematologica 101(4):506\u2013514. https:\/\/doi.org\/10.3324\/haematol.2015.136846","journal-title":"Haematologica"},{"key":"6662_CR22","unstructured":"Gerds TA (2019) Prodlim: product-limit estimation for censored event history analysis. https:\/\/cran.r-project.org\/package=prodlim"},{"issue":"7","key":"6662_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC De Wreede","year":"2011","unstructured":"De Wreede LC, Fiocco M, Putter H (2011) mstate: an R package for the analysis of competing risks and multi-state models. J Stat Softw 38(7):1\u201330. https:\/\/doi.org\/10.18637\/jss.v038.i07","journal-title":"J Stat Softw"},{"key":"6662_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-Verlag New York; New York"},{"key":"6662_CR25","unstructured":"Brunson JC, Read QD (2023) ggalluvial: alluvial plots in \u2018ggplot2\u2019.\u00a0http:\/\/corybrunson.github.io\/ggalluvial\/"},{"key":"6662_CR26","doi-asserted-by":"publisher","unstructured":"Krassowski M (2020) ComplexUpset. https:\/\/doi.org\/10.5281\/zenodo.3700590","DOI":"10.5281\/zenodo.3700590"},{"issue":"5","key":"6662_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjh.15691","volume":"184","author":"C Schmid","year":"2019","unstructured":"Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M et al (2019) Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the acute leukaemia working party of EBMT. Br J Haematol 184(5):782\u2013787. https:\/\/doi.org\/10.1111\/bjh.15691","journal-title":"Br J Haematol"},{"issue":"2","key":"6662_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41375-020-0863-4","volume":"35","author":"F Lorentino","year":"2021","unstructured":"Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B et al (2021) Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9\/10 or 10\/10 HLA-matched unrelated donors for acute leukemia. Leukemia 35(2):585\u2013594. https:\/\/doi.org\/10.1038\/s41375-020-0863-4","journal-title":"Leukemia"},{"issue":"2","key":"6662_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1172\/jci86175","volume":"127","author":"CA van Bergen","year":"2017","unstructured":"van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P et al (2017) Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. J Clin Investig 127(2):517\u2013529. https:\/\/doi.org\/10.1172\/jci86175","journal-title":"J Clin Investig"},{"issue":"6","key":"6662_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","volume":"22","author":"IS Moiseev","year":"2016","unstructured":"Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al (2016) Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant 22(6):1037\u20131042. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6662_CR31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1078-0432.Ccr-20-2809","volume":"27","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ et al (2021) Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res 27(3):843\u2013851. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2809","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6662_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","volume":"98","author":"Y Soltermann","year":"2019","unstructured":"Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S et al (2019) Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol 98(6):1485\u20131493. https:\/\/doi.org\/10.1007\/s00277-019-03673-3","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06662-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:10Z","timestamp":1763194750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06662-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6662"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06662-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee Leiden The Hague Delft (RP 22.002) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}